← back to search

Jennifer N. Durham

Bloomberg (United States) · US
Area of research
Oncology · Nutrition and Dietetics
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Vitamin C and Antioxidants Research, Pancreatic and Hepatic Oncology Research, and Cancer Genomics and Diagnostics.
h-index
30
citations
10,240
works
433
NIH funding
primary concept
Docetaxel
email

Recent publications

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
Nature Communications 2026cited by 4position: middledoi
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
Cancer Cell 2022cited by 177position: middledoi
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
Nature Cancer 2021cited by 342position: middledoi
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity
Cancer Cell 2021cited by 170position: middledoi
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Clinical Cancer Research 2020cited by 149position: middledoi
A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Clinical Cancer Research 2020cited by 125position: middledoi
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
Science 2019cited by 570position: middledoi
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Clinical Cancer Research 2019cited by 153position: middledoi
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Journal of Clinical Oncology 2019cited by 134position: middledoi
Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors
Clinical Cancer Research 2019cited by 64position: middledoi
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Journal for ImmunoTherapy of Cancer 2019cited by 45position: middledoi
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science 2017cited by 6,578position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dung T. Le · Johns Hopkins University6 papers (2019–2020)Luis A. Díaz · Secretaria de Salud4 papers (2019–2019)Bjarne R. Bartlett · State University of New York3 papers (2019–2019)Robert A. Anders · University of Baltimore3 papers (2019–2020)Elana J. Fertig · Genetic Resources Center2 papers (2020–2020)Daniel A. Laheru · NYU Langone Health2 papers (2020–2020)Elizabeth A. Sugar · Johns Hopkins University2 papers (2020–2020)Elizabeth M. Jaffee · NYU Langone Health2 papers (2020–2020)Beth Onners · Johns Hopkins Medicine2 papers (2020–2020)Andrew H. Ko · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2020–2020)Annie A. Wu · University of Calgary2 papers (2020–2020)Rajarsi Mandal · Northwell Health1 papers (2019–2019) · 1 papers (2019–2019)Barzin Y. Nabet · Gene Therapy Laboratory1 papers (2019–2019)Michael Considine · The University of Western Australia1 papers (2020–2020)Jonathan J. Havel · Acorda Therapeutics (United States)1 papers (2019–2019)Lisa M. Coussens · Cancer Research Center1 papers (2020–2020)Nadeem Riaz · New York Oncology Hematology1 papers (2019–2019)Matthew D. Hellmann · Weill Cornell Medicine1 papers (2019–2019)Ludmila Danilova · Convergence1 papers (2020–2020)